Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company ...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for ...
Strong Buy on WVE-N531 and WVE-006 catalysts, Phase data, and cash runway into 2028. Click for this WVE stock update.
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through ...
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...
Pharmaceutical Technology on MSN
Gilead Sciences completes Tubulis acquisition for $5bn
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Sellas Life Sciences Group Inc SLS shares are trading higher on Wednesday as traders react to the company's latest update on ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to ...
Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results